Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory
and clinical investigations related to revascularization therapies in cardiovascular medicine.
Cardiovascular Revascularization
Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell
therapy, pharmacological interventions, restenosis management; and prevention, including experiments conducted
in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary
and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, congenital heart disease, coronary heart disease,
epidemiology, genetics, health services and outcomes research, invasive imaging, molecular cardiology, preventive cardiology, and vascular
medicine.
Cardiovascular Revascularization Medicine will consider all articles describing clinical trials and translational
research (ie, those that unite the clinic with the laboratory). The Journal publishes original articles, rapid communications, reviews,
technical notes, teaching editorials, and special features. Original articles that address any aspect of cardiovascular revascularization
medicine are invited. Letters to the http://www.journals.elsevier.com/cardiovascular-revascularization-medicine/editorial-board/Editor
and interesting images are encouraged.
https://www.mea.elsevierhealth.com/cardiovascular-revascularization-medicine-15538389.html109259Cardiovascular Revascularization Medicinehttps://www.mea.elsevierhealth.com/media/catalog/product/1/5/15538389_31.jpg00USDOutOfStock/Revues28526128204 <IT>Cardiovascular Revascularization Medicine (CRM)</IT> is an international and multidisciplinary journal that publishes original laboratory
and clinical investigations related to <B>revascularization therapies</B> in <B>cardiovascular medicine</B>.<P>
<IT>Cardiovascular Revascularization
Medicine</IT> publishes articles related to preclinical work and <B>molecular interventions</B>, including <B>angiogenesis</B>, <B>cell
therapy</B>, <B>pharmacological</B> interventions, <B>restenosis management</B>; and <B>prevention</B>, including experiments conducted
in human subjects, in laboratory animals, and <IT>in vitro</IT>. Specific areas of interest include percutaneous angioplasty in coronary
and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, congenital heart disease, coronary heart disease,
epidemiology, genetics, health services and outcomes research, invasive imaging, molecular cardiology, preventive cardiology, and vascular
medicine.
<P><IT>Cardiovascular Revascularization Medicine</IT> will consider all articles describing clinical trials and translational
research (ie, those that unite the clinic with the laboratory). The Journal publishes original articles, rapid communications, reviews,
technical notes, teaching editorials, and special features. Original articles that address any aspect of cardiovascular revascularization
medicine are invited. Letters to the <URL><HREF>http://www.journals.elsevier.com/cardiovascular-revascularization-medicine/editorial-board/</HREF><HTXT>Editor</HTXT></URL>
and interesting images are encouraged.
USD001553-8389JOURNALELSEVIERIN STOCK1553-8389Volume 20journalsJournalsNoNoNoNoPlease SelectPlease SelectPlease Select